These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23041275)

  • 1. Orally active desulfated low molecular weight heparin and deoxycholic acid conjugate, 6ODS-LHbD, suppresses neovascularization and bone destruction in arthritis.
    Hwang SR; Seo DH; Al-Hilal TA; Jeon OC; Kang JH; Kim SH; Kim HS; Chang YT; Kang YM; Yang VC; Byun Y
    J Control Release; 2012 Nov; 163(3):374-84. PubMed ID: 23041275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
    Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
    J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate.
    Lee DY; Kim SK; Kim YS; Son DH; Nam JH; Kim IS; Park RW; Kim SY; Byun Y
    J Control Release; 2007 Apr; 118(3):310-7. PubMed ID: 17291620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys.
    Lee YK; Kim SK; Lee DY; Lee S; Kim CY; Shin HC; Moon HT; Byun Y
    J Control Release; 2006 Apr; 111(3):290-8. PubMed ID: 16497407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant.
    Park JW; Jeon OC; Kim SK; Al-Hilal TA; Lim KM; Moon HT; Kim CY; Byun Y
    Thromb Haemost; 2011 Jun; 105(6):1060-71. PubMed ID: 21437357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid.
    Alam F; Al-Hilal TA; Chung SW; Seo D; Mahmud F; Kim HS; Kim SY; Byun Y
    Biomaterials; 2014 Aug; 35(24):6543-52. PubMed ID: 24816287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation.
    Kim SK; Vaishali B; Lee E; Lee S; Lee YK; Kumar TS; Moon HT; Byun Y
    Thromb Res; 2006; 117(4):419-27. PubMed ID: 15913716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.
    Kim SK; Lee DY; Kim CY; Nam JH; Moon HT; Byun Y
    J Control Release; 2007 Nov; 123(2):155-63. PubMed ID: 17884230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular delivery of desulfated heparin with bile acid conjugation alleviates T cell-mediated inflammatory arthritis via inhibition of RhoA-dependent transcellular diapedesis.
    Kang JH; Hwang SR; Sung S; Jang JA; Alam MM; Sa KH; Kim SY; Kim IS; Byun YR; Kang YM
    J Control Release; 2014 Jun; 183():9-17. PubMed ID: 24657949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant efficacy of solid oral formulations containing a new heparin derivative.
    Park JW; Jeon OC; Kim SK; Al-Hilal TA; Moon HT; Kim CY; Byun Y
    Mol Pharm; 2010 Jun; 7(3):836-43. PubMed ID: 20349950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent.
    Lee Y; Nam JH; Shin HC; Byun Y
    Circulation; 2001 Dec; 104(25):3116-20. PubMed ID: 11748110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligomeric bile acid-mediated oral delivery of low molecular weight heparin.
    Al-Hilal TA; Park J; Alam F; Chung SW; Park JW; Kim K; Kwon IC; Kim IS; Kim SY; Byun Y
    J Control Release; 2014 Feb; 175():17-24. PubMed ID: 24333628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention effect of orally active heparin conjugate on cancer-associated thrombosis.
    Al-Hilal TA; Alam F; Park JW; Kim K; Kwon IC; Ryu GH; Byun Y
    J Control Release; 2014 Dec; 195():155-61. PubMed ID: 24862320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis.
    Lee DY; Park K; Kim SK; Park RW; Kwon IC; Kim SY; Byun Y
    Clin Cancer Res; 2008 May; 14(9):2841-9. PubMed ID: 18451252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates.
    Kim SK; Lee EH; Vaishali B; Lee S; Lee YK; Kim CY; Moon HT; Byun Y
    J Control Release; 2005 Jun; 105(1-2):32-42. PubMed ID: 15925422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant.
    Kim SK; Lee DY; Lee E; Lee YK; Kim CY; Moon HT; Byun Y
    J Control Release; 2007 Jul; 120(1-2):4-10. PubMed ID: 17490773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic efficacy of an oral low molecular weight heparin conjugated with deoxycholic asset on microsurgical anastomosis in rats.
    Eom JS; Koh KS; Al-Hilal TA; Park JW; Jeon OC; Moon HT; Byun Y
    Thromb Res; 2010 Sep; 126(3):e220-4. PubMed ID: 20619883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sigma receptor-mediated targeted delivery of anti-angiogenic multifunctional nanodrugs for combination tumor therapy.
    Li Y; Wu Y; Huang L; Miao L; Zhou J; Satterlee AB; Yao J
    J Control Release; 2016 Apr; 228():107-119. PubMed ID: 26941036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention effect of orally active heparin derivative on deep vein thrombosis.
    Kim SK; Lee DY; Kim CY; Moon HT; Byun Y
    Thromb Haemost; 2006 Aug; 96(2):149-53. PubMed ID: 16894457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.